Encysive puts trials of TBC3711 on hold after "unusual finding"

New York, March 23 - Encysive Pharmaceuticals Inc. said it and the Food and Drug Administration have halted studies of TBC3711, a next-generation selective endothelin receptor antagonist.

The drugs was in early clinical studies.

Encysive said the action follows an "unusual finding" after dosing with intravenous TBC3711 in a single rat that had displayed abnormalities at baseline.

The delay follows a standard 30-day review process associated with the Investigational New Drug application for the intravenous form of TBC3711.

Encysive said it agrees with the FDA view that the finding requires further review before any patients are given TBC3711.

Encysive is a Houston-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.